Study reveals non-statin cholesterol drugs could reduce liver cancer risk
The third leading cause of cancer mortality accounts for over 700,000 deaths every year
Read More
Tag: liver cancer
US researchers reveal positive results of personalised vaccine for liver cancer
Hepatocellular carcinoma is one of the leading causes of cancer-related deaths worldwide
Read More
NHS roaming trucks identify over 2000 people at risk of liver cancer
The NHS has been visiting at-risk communities to detect liver cancer earlier
Read More
Roche’s Tecentriq/Avastin combo improves survival in liver cancer
Updated analysis is from the Phase III IMbrave150 study
Read More
US rejects MSD/Eisai’s Keytruda Lenvima combo
Regulators rejected accelerated approval as Roche’s combination for the same patient population made it over the line first
Read More
Roche’s Tecentriq/Avastin combo wins US approval
Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen cleared to treat unresectable or metastatic liver cancer
Read More
NICE recommends Lenvima for advanced liver cancer
The National Institute for Health and Care excellence (NICE) has recommended Eisai and MSD’s Lenvima, a potentially life-extending treatment for adults with advanced liver cancer.
Read More
Bayer’s Stivarga wins NICE backing for advanced liver cancer
Bayer’s Stivarga has been recommended for use on the NHS by the National Institute for Health and Care Excellence (NICE) following a rapid review of guidance published earlier in the year.
Read More
Ipsen’s Cabometyx wins EU nod for liver cancer
Ipsen’s Cabometyx can now be used as monotherapy to treat certain patients with liver cancer following a green light from regulators in Europe.
Read More
MSD’s Keytruda approved for liver cancer
US regulators have expanded the use of MSD’s anti-PD-1 therapy Keytruda to include treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
Read More
Eisai/MSD’s Lenvima approved in Europe for liver cancer
Eisai and MSD’s Lenvima has won approval in the EU as a first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
Read More
Liver cancer patients barred from NHS access to Bayer’s Stivarga
It is now looking very unlikely that patients with liver cancer will get access to Bayer’s Stivarga on the NHS, after cost regulators issued final draft guidelines rejecting funding for the drug in this setting.
Read More
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
